Browse drugs

…ses decreased mortality and morbidity, but the effectiveness of mycophenolate immunosuppression treatment reduces ILD progression by 75.5%. T…

…cline in use of cyclophosphamide from 2013 onwards. Ever-use of mycophenolate began to rise from the group recruited from1994 onwards and bio…

…addition of two immunosuppressive therapies, anchored on either belimumab or voclosporin.3 4 Glucocorticoids should be administered initi…

…ed cyclophosphamide had more infections than those who received mycophenolate. Methotrexate was associated with lower infection rates than my…

…tologic (lymphopenia), and serologic activity (SLEDAI-2K 6–8 on prednisolone 10 mg/day).Results In August 2024, anifrolumab 300 mg IV monthl…

…hibitor (voclosporin or tacrolimus), or iii) mycophenolate with obinutuzumab. Following renal response, treatment should continue for at lea…

… baseline HRCT predicted PPF in patients with SSc-ILD receiving mycophenolate or cyclophosphamide therapy. Future independent prospective coh…

…ticularly in patients with recent diagnoses and those receiving mycophenolate. These findings highlight subgroups of patients who may be at i…

…tations at presentation and were less likely to be treated with cyclophosphamide, mycophenolate or biologics but developed more damage.…

… of their monitoring over the first 6 weeks. In patients taking mycophenolate, this was 13% and 50% respectively. In contrast to other specia…

…h a favourable safety profile compared with glucocorticoids and mycophenolate. While the current literature lacks robust trials, case reports…

…other authors. Alternative immunosuppressive treatments include mycophenolate, cyclosporine, rituximab and intravenous immunoglobulin but the…